Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

v3.21.2
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Jul. 31, 2021
Accounting Policies [Abstract]  
Schedule of net accounts receivable by segment
    July 31, 2021     July 31, 2020  
Net accounts receivable by segment   Amount     %     Amount     %  
Clinical Labs (by billing category)                        
Third party payers   $ 2,195       36     $ 2,455       40  
Patient self-pay     2,007       33       2,044       33  
Medicare     1,122       19       884       14  
HMO’s     692       12       797       13  
Total Clinical Labs     6,016       100 %     6,180       100 %
Total Life Sciences     4,182               2,961          
Total accounts receivable – net   $ 10,198             $ 9,141          

 
Schedule of basic and diluted net income (loss) per share
    2021     2020     2019  
Net income (loss)   $ 7,875     $ (28,520 )   $ 2,489  
                         
Weighted-average common shares outstanding – basic     48,191       47,696       47,351  
Add: effect of dilutive stock options and restricted stock     134      
—
       125  
Weighted-average common shares outstanding – diluted     48,325       47,696       47,476  
                         
Net (loss) income per share – basic   $ 0.16     $ (0.60 )   $ 0.05  
Net (loss) income per share – diluted   $ 0.16     $ (0.60 )   $ 0.05  

 
Schedule of expenses related share-based payment arrangements
    2021     2020     2019  
Cost of clinical laboratory services   $ 93     $ 46     $ —  
Selling, general and administrative     814       887       939  
    $ 907     $ 933     $ 939